Clinical trial
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
NCT00239980 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00239980 |
|---|---|
| Title | Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) |
| Official title | A Phase II Randomized Study of Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | dalteparin |
| Enrollment | 77 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Oct 17, 2005 |
| Last update posted | Feb 3, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: